Contineum Therapeutics
CTNM
62 hedge funds and large institutions have $231M invested in Contineum Therapeutics in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 10 reducing their positions, and 3 closing their positions.
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
180% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 10
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more funds holding
Funds holding: 52 → 62 (+10)
10.65% more ownership
Funds ownership: 72.22% → 82.87% (+11%)
11% less capital invested
Capital invested by funds: $258M → $231M (-$27.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$7.85M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.51M |
| 3 |
SC
Stempoint Capital
New York
|
+$4.21M |
| 4 |
BlackRock
New York
|
+$3.15M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$2.74M |
| 2 |
Squarepoint
New York
|
-$2.1M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.28M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.19M |
| 5 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$744K |
CTNM Hedge Fund Activity: Q4 2024 in Review
62 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q4 2024, worth a combined $231M — down 11% from $258M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CTNM positions and 3 closed out — a net gain of 10 holders — while 28 added to existing stakes and 10 trimmed.
The largest buyer was Saturn V Capital Management, adding an estimated $7.85M. The largest seller was Polar Capital Holdings, cutting an estimated $2.74M.
- 62 institutional investors held Contineum Therapeutics (CTNM) as of Q4 2024, up from 52 in Q3 2024.
- Funds reported $231M of Contineum Therapeutics stock for Q4 2024, down 11% quarter-over-quarter.
- 13 funds opened new Contineum Therapeutics positions in Q4 2024 and 3 closed out, a net change of +10 holders.
- The largest Contineum Therapeutics buyer in Q4 2024 was Saturn V Capital Management, an estimated $7.85M added.
- The largest Contineum Therapeutics seller in Q4 2024 was Polar Capital Holdings, an estimated $2.74M sold.
Based on aggregated 13F filings for Q4 2024.